TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

Interventional cardiologist Foluso Fakorede, MD, opened a practice in rural Mississippi, the epicenter of the PAD and CLI epidemic, to try and reverse the glaring health disparities in that region.

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said. 

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

The rumors, it seems, were true. Once the deal is finalized, Shockwave Medical will operate as a business unit within Johnson & Johnson MedTech.

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR. 

San Francisco-based Osso VR and the American College of Cardiology have collaborated on advanced LAAO simulations. The two groups first started working together back in 2022. 

The recall is due to ongoing concerns about the devices breaking. Three patients have been injured as a result of this issue.